Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-03-27 00:00:00 ET · period of report 2026-03-02 · accession 0002001011-26-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-27 | 2026-03-02 | LGND | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +10.5K | 199.4K | +6% | $0 |
| D | 2026-03-27 | 2026-03-02 | LGND | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +50.1K | 50.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | A | A | 10,495 | $0.00 | 199,381 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2027; February 15, 2028; and February 15, 2029, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan, delivery of shares otherwise issuable upon each vesting date will be deferred. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2026-03-02 | A | A | 50,058 | $0.00 | 50,058 | D | $202.55 · — to 2036-03-02 | 50,058 Common Stock | (F2) The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. |